Pharmacogenomics: information on human genetic variance is only just beginning to be used in drug development
Article Abstract:
Understanding patient response to various drugs at a molecular level would help drug companies to taylor therapies for individual patients.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Emerging themes in medicinal glycoscience
Article Abstract:
Simplification of, and easier access to, complex carbohydrates and glycoconjugates allows for research into their therapeutic uses.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Structure-aided drug design's next generation
Article Abstract:
The structure-aided design has an advantage over other facilities as it is focused on the identification and refinement of drug leads, which can be patented and ultimately put in the clinic. One of the disadvantages of structure based drug design is that it theoretically places a limit on the kind of target a company can pursue.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Genomic integration and gene expression by a modified adenoviral vector. Genomic integration and gene expression by modified adenoviral vector
- Abstracts: Optical tracking and detection of immunomagnetically selected and aligned cells. In vivo visualization of gene expression using magnetic resonance imaging
- Abstracts: quantum-dot-tagged microbeads for multiplexed optical coding of biomolecules. Taking a census of mRNA populations with microbeads
- Abstracts: Manipulation of human minichromosomes to carry greater than megabase-sized chromosome inserts. Production of cattle lacking prion protein
- Abstracts: progress against HIV: the need for new treatments for AIDS is more urgent than ever. Slimy business-the biotechnology of biofilms